Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11511829 | 0.87 | MEN1 (0.55) | MAOBMEN1ALDH1A1MAPTTHRB | |
| SCHEMBL6692354 | 0.87 | PPARA (0.54) | MAOBPPARAMEN1MAPTKMT2A | |
| SCHEMBL4170185 | 0.84 | HIF1A (0.62) | MEN1ALDH1A1MAPTTHRBPKM | |
| SCHEMBL1966732 | 0.83 | NLRP3 (0.59) | MAOBPPARAMEN1RECQLRAB9A | |
| SCHEMBL11510145 | 0.82 | HIF1A (0.64) | MAOBMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL11511619 | 0.81 | FFAR1 (0.61) | MEN1LMNAKMT2ABCHEACHE | |
| SCHEMBL11511650 | 0.80 | HIF1A (0.54) | MAOBALDH1A1LMNAMAPTPKM | |
| SCHEMBL10055035 | 0.80 | HPGD (0.67) | PPARAMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL4092017 | 0.79 | EGFR (0.50) | MAOBPPARAMEN1MAPTKMT2A | |
| SCHEMBL11511510 | 0.79 | ARG1 (0.71) | MAOBPKMBCHEACHEHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054888-A1 | NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-03-08 | — | — | US | disclosed |
| US-7166601-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7112586-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060183741-A1 | Treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome | JOHNSON SIGMOND G | 2006-08-17 | — | — | US | disclosed |
| US-6967199-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050148584-A1 | Novel substituted diamine derivatives useful as motilin antagonists | JOHNSON SIGMOND G (US) | 2005-07-07 | — | — | US | disclosed |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | JOHNSON SIGMONG G (US) | 2003-10-30 | — | — | US | disclosed |
| CN-1440390-A | Substituted diamine derivatives as motilin antagonists | ORTHO MCNEIL PHARM INC (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6511980-B2 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054888-A1 | NOVEL SUBSTITUTED DIAMINE DERIVATIVES USEFUL AS MOTILIN AGONISTS | MLNR, NPY4R, GIPR | MAOB 523/4885PPARA 3022/4885MEN1 580/4885 |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | MAOB 383/4885PPARA 3139/4885MEN1 604/4885 |
| US-20060183741-A1 | Treatment of associated conditions and disorders such as gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel syndrome | MLNR, NPY4R, GIPR | MAOB 389/4885PPARA 3245/4885MEN1 405/4885 |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | MAOB 508/4885PPARA 1768/4885MEN1 966/4885 |
| US-20050148584-A1 | Novel substituted diamine derivatives useful as motilin antagonists | MLNR, NPY4R, GIPR | MAOB 456/4885PPARA 3743/4885MEN1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.